This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

The MPN Research Foundation And LLS Partner For A Second Round Of The Myelofibrosis Challenge

CHICAGO and WHITE PLAINS, N.Y., Feb. 14, 2013 /PRNewswire/ -- In 2012, The Myeloproliferative Neoplasm (MPN) Research Foundation and The Leukemia & Lymphoma Society (LLS) jointly issued the MF Challenge Grant, seeking innovative approaches to reversing fibrosis in patients with myelofibrosis (MF). The challenge resulted in many high quality applications, therefore, the two organizations are continuing with a second round of applications. 

Applicants for this concept grant program will have until April 1, 2013 to submit their proposal for funding of up to $100,000 per grant. The grant review will take place in May 2013.

"Concept grants" are used to identify innovative and novel approaches to an issue. Since the objective is to identify and fund new approaches to fibrosis, applicants are not required to have preliminary data. Success for a grant is defined as proving an idea is worth pursuing further.

Fibrosis is the formation of excessive fibrous connective tissue in place of healthy tissue. The disease myelofibrosis (one of the myeloproliferative neoplasms) is characterized by fibrosis in the bone marrow.  Though some patients may live for many years with relatively mild symptoms, others have a much bleaker outlook. The only potential cure for MF is a stem cell transplant, which is an option for only a small number of MF patients.  The disease in a small proportion of MF patients can transform to acute myeloid leukemia (AML), a highly lethal type of blood and bone marrow cancer that progresses rapidly.

MPN Research Foundation President Barbara Van Husen says this grant program has already stimulated scientific interest in myelofibrosis.

"It is our hope that by bringing a broad range of experts to focus on myelofibrosis we can capitalize on important research in other areas of fibrosis and cancer research for the benefit of MPN patients and many others," Van Husen said.

"LLS aggressively and proactively searches for opportunities to improve the lives of patients by funding areas of research addressing critical unmet medical needs. The lack of a cure for the majority of patients with myelofibrosis presents a challenge that we must address," said Richard C. Winneker, Ph.D., LLS senior vice president, research. "LLS looks forward to our continued partnership with the MPN Research Foundation for a second year to meet the challenge for patients with myelofibrosis."

About The Myeloproliferative Research Foundation The MPN Research Foundation was started in 2000. Founded by patients, for patients, terms on every research grant are negotiated to maximize the dollars invested in actual research. The Foundation's esteemed Scientific Advisory Board utilizes a rigorous selection process to ensure donations are allocated to the most innovative research projects. To date, the Foundation has awarded over nine million dollars for MPN research. The MPN Research Foundation has received funding from MPN patients and from Sanofi Oncology and Incyte Corporation to help support the MF Challenge.  To learn more about the Foundation, visit www.mpnresearchfoundation.org.

About The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.  Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada.  To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org

Media contact: Andrea Greif, (914) 821-8958, andrea.greif@lls.org.

SOURCE The Leukemia & Lymphoma Society

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,614.81 +215.14 1.31%
S&P 500 1,941.28 +37.27 1.96%
NASDAQ 4,419.4780 +103.4040 2.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs